Cancer Antibodies: Competitive Positioning for Success

Published by: BioSeeker Group AB

Published: Jun. 3, 2008 - 261 Pages

Table of Contents

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

4.1 List of Figures

4.2 List of Tables

5 How to Use this Report

6 Antibody Target Localization

7 The Cancer Genome Project and Antibody Targets

7.1 Antibody Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

8 Protein Expression Profiles of Antibody Drug Targets in Human

8.1 Expression in Normal Tissues and Cancer Tissues

8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Antibody Drugs

10 Protein-Protein Interactions Among Identified Antibody Targets

11 Available Biological Structure Data on Antibody Targets

12 Drug Target Profiles of Antibody Targets in Oncology

12.1.1 Auxiliary Transport Protein Activity

12.1.2 Carboxypeptidase Activity

12.1.3 Catalytic Activity

12.1.4 Cell Adhesion Molecule Activity

12.1.5 Chemokine Activity

12.1.6 Cofactor Binding

12.1.7 Complement Activity

12.1.8 Cytokine Activity

12.1.9 DNA Topoisomerase Activity

12.1.10 Extracellular Matrix Structural Constituent

12.1.11 G-Protein Coupled Receptor Activity

12.1.12 Growth Factor Activity

12.1.13 Hormone Activity

12.1.14 Hydrolase Activity

12.1.15 Intracellular Ligand-Gated Ion Channel Activity

12.1.16 Metallopeptidase Activity

12.1.17 MHC Class I Receptor Activity

12.1.18 Molecular Function Unknown

12.1.19 Oxidoreductase Activity

12.1.20 Peptidase Activity

12.1.21 Protease Inhibitor Activity

12.1.22 Protein Binding

12.1.23 Receptor Activity

12.1.24 Receptor Binding

12.1.25 Receptor Signaling Complex Scaffold Activity

12.1.26 RNA-Directed DNA Polymerase Activity

12.1.27 Serine-Type Peptidase Activity

12.1.28 T Cell Receptor Activity

12.1.29 Translation Regulator Activity

12.1.30 Transmembrane Receptor Activity Kinase Activity

12.1.32 Unclassified

13 The Antibody-Target Interactome

14 The Progression and Maturity of Antibody Targets in Oncology: The Preclinical Explosion

14.1 Target Profiles of Cancer Antibodies in Pre-Registration or on the Market

14.2 New Cancer Antibody Targets in Phase III Clinical Development

14.3 New Cancer Antibody Targets in Phase II Clinical Development

14.4 New Cancer Antibody Targets in Phase I Clinical Development

14.5 New Cancer Antibody Targets in Preclinical Development

14.6 Development Profiles of All Identified Cancer Antibody Targets

15 Competitive Peer Group Profiling of Antibody Drugs by Cancer Indication

15.1 Biliary Cancer

15.2 Bladder Cancer

15.3 Bone Cancer

15.4 Brain Cancer

15.5 Breast Cancer

15.6 Cervical Cancer

15.7 Colorectal Cancer

15.8 Endometrial Cancer

15.9 Fallopian Tube Cancer

15.10 Gastrointestinal Cancer

15.10.1 Gastrointestinal Stomach Cancer

15.11 Head and Neck Cancer

15.12 Leukemia

15.12.1 Acute Lymphocytic Leukemia

15.12.2 Acute Myelogenous Leukemia

15.12.3 Chronic Lymphocytic Leukemia

15.12.4 Chronic Myelogenous Leukemia

15.13 Liver Cancer

15.14 Lung Cancer

15.14.1 Non-Small Cell Lung Cancer

15.14.2 Small Cell Lung Cancer

15.15 Lymphoma

15.15.1 B-Cell Lymphoma

15.15.2 Hodgkin’s Lymphoma

15.15.3 Non-Hodgkin’s Lymphoma

15.15.4 T-Cell Lymphoma

15.16 Melanoma

15.17 Mesothelioma

15.18 Myelodysplastic Syndrome

15.19 Myeloma

15.20 Nasopharyngeal Cancer

15.21 Neuroblastoma Cancer

15.22 Oesophageal Cancer

15.23 Ovarian Cancer

15.24 Pancreatic Cancer

15.25 Peritoneal Cancer

15.26 Prostate Cancer

15.27 Renal Cancer

15.28 Sarcoma

15.29 Supportive Care Indications

15.29.1 Chemotherapy-Induced Bone Marrow Injury

15.29.2 Chemotherapy-Induced Anemia

15.30 Thyroid Cancer

16 Cancer Antibodies and Their Targets by Companies

16.1 Australia

16.2 Belgium

16.3 Brazil

16.4 Canada

16.5 China

16.6 Cuba

16.7 Denmark

16.8 France

16.9 Germany

16.10 Israel

16.11 Italy

16.12 Japan

16.13 Netherlands

16.14 New Zealand

16.15 Norway

16.16 South Korea

16.17 Sweden

16.18 Switzerland

16.19 United Kingdom

16.20 USA

16.21 Non Industrial Bodies

17 Disclaimer

18 Drug Index

19 Company Index

4.1 List of Figures

Figure 1: Primary Sub-cellular Localization of Drug Targets

Figure 2: Visualization of Protein-Protein Interactions Among Antibody Drug Targets

Figure 3: The Drug-Protein Interactome of Antibody Drugs in Oncology

Figure 4: Direct Head-to-Head Targeting Interactome of Cancer Antibody Drugs

Figure 5: Competitive Peer Group Profiling Example

4.2 List of Tables

Table 1: Primary and Alternate Localization of Antibody Drug Targets

Table 2: Drug Targets of Cancer Antibodies Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census

Table 3: Available Protein Expression Profiles of Antibody Drug Targets

Table 4: Pathway Summary

Table 5: Drug Targets Without any Identified Assigned Pathways

Table 6: Pathway Profile According to BioCarta of Cancer Antibody Drug Targets

Table 7: Pathway Profile According to KEGG of Cancer Antibody Drug Targets

Table 8: Cancer Antibodies Targeting Major Singaling Pathways

Table 9: Protein-Protein Interactions Among Antibody Drug Targets

Table 10: Number of Available Biological Structures of Cancer Antibody Targets

Table 11: Overview of Drug Target Profile Themes

Table 12: Antibody-Protein Interactome Clusters

Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the

Presence of New Drug Target Mixes by Developmental Stage

Table 14: Top 5 Pursued Cancer Antibody Targets

Table 15: Target Profiles of Cancer Antibodies in Pre-Registration or on the Market

Table 16: New Cancer Antibody Targets in Phase III Clinical Development

Table 17: New Cancer Antibody Targets in Phase II Clinical Development

Table 18 New Cancer Antibody Targets in Phase I Clinical Development

Table 19: New Cancer Antibody Targets in Preclinical Development

Table 20: The Progression, Maturity and Competitive Comparison of Antibody Drug Targets in Development

Table 21: Number of Cancer Antibody Drug Target Mixes Reported by Cancer Indication

Table 22: Step 1 - Indication Profile of Peer Drugs

Table 23: Step 2 - All Peer Drugs with Known Cancer Indications

Table 24: Step 3 - Submarine Peer Drugs

Table 25: Step 4 -Target Overlap Drugs to Peer Drugs

Table 26: Drug Targets of Antibodies for the Treatment of Biliary Cancer According to Developmental Stage of

Antibody

Table 27: Drug Targets of Antibodies for the Treatment of Bladder Cancer According to Developmental Stage of

Antibody

Table 28: Drug Targets of Antibodies for the Treatment of Bone Cancer According to Developmental Stage of

Antibody

Table 29: Drug Targets of Antibodies for the Treatment of Brain Cancer According to Developmental Stage of

Antibody

Table 30: Drug Targets of Antibodies for the Treatment of Breast Cancer According to Developmental Stage of

Antibody

Table 31: Drug Targets of Antibodies for the Treatment of Cervical Cancer According to Developmental Stage of

Antibody

Table 32: Drug Targets of Antibodies for the Treatment of Colorectal Cancer According to Developmental Stage

of Antibody

Table 33: Drug Targets of Antibodies for the Treatment of Endometrial Cancer According to Developmental

Stage of Antibody

Table 34: Drug Targets of Antibodies for the Treatment of Fallopian Tube Cancer According to Developmental

Stage of Antibody

Table 35: Drug Targets of Antibodies for the Treatment of Gastrointestinal Cancer (general) According to

Developmental Stage of Antibody

Table 36: Drug Targets of Antibodies for the Treatment of Gastrointestinal Stomach Cancer According to

Developmental Stage of Antibody

Table 37: Drug Targets of Antibodies for the Treatment of Head and Neck Cancer According to Developmental

Stage of Antibody

Table 38: Drug Targets of Antibodies for the Treatment Leukemia (general) According to Developmental Stage

of Antibody

Table 39: Drug Targets of Antibodies for the Treatment of Acute Lymphocytic Leukemia According to

Developmental Stage of Antibody

Table 40: Drug Targets of Antibodies for the Treatment of Acute Myelogenous Leukemia According to

Developmental Stage of Antibody

Table 41: Drug Targets of Antibodies for the Treatment of Chronic Lymphocytic Leukemia According to

Developmental Stage of Antibody

Table 42: Drug Targets of Antibodies for the Treatment of Chronic Myelogenous Leukemia According to

Developmental Stage of Antibody

Table 43: Drug Targets of Antibodies for the Treatment of Liver Cancer According to Developmental Stage of

Antibody

Table 44: Drug Targets of Antibodies for the Treatment of Lung Cancer (general) According to Developmental

Stage of Antibody

Table 45: Drug Targets of Antibodies for the Treatment of Non Small Cell Lung Cancer According to

Developmental Stage of Antibody

Table 46: Drug Targets of Antibodies for the Treatment of Small Cell Lung Cancer According to Developmental

Stage of Antibody

Table 47: Drug Targets of Antibodies for the Treatment of lymphoma (general) According to Developmental

Stage of Antibody

Table 48: Drug Targets of Antibodies for the Treatment of B cell Lymphoma According to Developmental Stage

of Antibody

Table 49: Drug Targets of Antibodies for the Treatment of Hodgkin’s Lymphoma According to Developmental

Stage of Antibody

Table 50: Drug Targets of Antibodies for the Treatment of Non Hodgkin’s Lymphoma According to

Developmental Stage of Antibody

Table 51: Drug Targets of Antibodies for the Treatment of T cell Lymphoma According to Developmental Stage

of Antibody

Table 52: Drug Targets of Antibodies for the Treatment of Melanoma According to Developmental Stage of

Antibody

Table 53: Drug Targets of Antibodies for the Treatment of Mesothelioma According to Developmental Stage of

Antibody

Table 54: Drug Targets of Antibodies for the Treatment of Myelodysplastic Syndrome According to

Developmental Stage of Antibody

Table 55: Drug Targets of Antibodies for the Treatment of Myeloma According to Developmental Stage of

Antibody

Table 56: Drug Targets of Antibodies for the Treatment of Nasopharyngeal Cancer According to Developmental

Stage of Antibody

Table 57: Drug Targets of Antibodies for the Treatment of Neuroblastoma Cancer According to Developmental

Stage of Antibody

Table 58: Drug Targets of Antibodies for the Treatment of Oesophageal Cancer According to Developmental

Stage of Antibody

Table 59: Drug Targets of Antibodies for the Treatment of Ovarian Cancer According to Developmental Stage of

Antibody

Table 60: Drug Targets of Antibodies for the Treatment of Pancreatic Cancer According to Developmental Stage

of Antibody

Table 61: Drug Targets of Antibodies for the Treatment of Peritoneal Cancer According to Developmental Stage

of Antibody

Table 62: Drug Targets of Antibodies for the Treatment of Prostate Cancer According to Developmental Stage of

Antibody

Table 63: Drug Targets of Antibodies for the Treatment of Renal Cancer According to Developmental Stage of

Antibody

Table 64: Drug Targets of Antibodies for the Treatment of Sarcoma According to Developmental Stage of

Antibody

Table 65: Drug Targets of Antibodies for the Treatment of Chemotherapy-Induced Bone Marrow Injury

According to Developmental Stage of Antibody

Table 66: Drug Targets of Antibodies for the Treatment of Chemotherapy-Induced Anemia According to

Developmental Stage of Antibody

Table 67: Drug Targets of Antibodies for the Treatment of Thyroid Cancer According to Developmental Stage of

Antibody

Table 68: Antibodies with Drug Target Mix and Developmental Projects by Companies in Australia

Table 69: Antibodies with Drug Target Mix and Developmental Projects by Companies in Belgium

Table 70: Antibodies with Drug Target Mix and Developmental Projects by Companies in Brazil

Table 71: Antibodies with Drug Target Mix and Developmental Projects by Companies in Canada

Table 72: Antibodies with Drug Target Mix and Developmental Projects by Companies in China

Table 73: Antibodies with Drug Target Mix and Developmental Projects by Companies in Cuba

Table 75: Antibodies with Drug Target Mix and Developmental Projects by Companies in France

Table 76: Antibodies with Drug Target Mix and Developmental Projects by Companies in Germany

Table 77: Antibodies with Drug Target Mix and Developmental Projects by Companies in Israel

Table 78: Antibodies with Drug Target Mix and Developmental Projects by Companies in Italy

Table 79: Antibodies with Drug Target Mix and Developmental Projects by Companies in Japan

Table 80: Antibodies with Drug Target Mix and Developmental Projects by Companies in the Netherlands

Table 81: Antibodies with Drug Target Mix and Developmental Projects by Companies in New Zealand

Table 82: Antibodies with Drug Target Mix and Developmental Projects by Companies in Norway

Table 83: Antibodies with Drug Target Mix and Developmental Projects by Companies in South Korea

Table 84: Antibodies with Drug Target Mix and Developmental Projects by Companies in Sweden

Table 85: Antibodies with Drug Target Mix and Developmental Projects by Companies in Switzerland

Table 86: Antibodies with Drug Target Mix and Developmental Projects by Companies in United Kingdom

Table 87: Antibodies with Drug Target Mix and Developmental Projects by Companies in the USA

Table 88: Antibodies with Drug Target Mix and Developmental Projects by Non-Industrial Bodies

Abstract

Executive Summary

This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the cancer antibody field and identified 145 drug targets belonging to 253 antibodies. This report, Cancer Antibodies: Competitive Positioning for Success, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer antibody drugs.

In the report, BioSeeker reports on 147 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 253 cancer antibody drugs designed for the treatment of 42 different cancer indications. The highest degree of distinctiveness among cancer antibodies is achieved by sorting each of them according to targeted cancer indication and drug target mix. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of cancer antibodies. No less than 165 protein-protein interactions were recognized among and between 98 of the 145 included antibody drug targets.

Why You Should Own Your Own Copy of this Report:

• 260+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
• A 253 cancer antibody drugs analysis, under development by 102 investigators, covering 480 developmental projects in cancer
• 145 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other antibody drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
• A unique drug target combination breakdown of cancer antibodies into tumor type and developmental stage
• Unique drug-protein target interactome- and protein-protein of drug targets interactome analysis
• Pathway profiling of cancer antibody drug targets
• Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
• Who are working on sequels to blockbuster drugs?
• Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.